<DOC>
	<DOCNO>NCT00336674</DOCNO>
	<brief_summary>In people type 1 diabetes beta cell pancreas longer make insulin body 's immune system attack destroyed beta cell . It think exposure mucous membrane insulin may cause act like vaccine effect whereby protective immune cell stimulate counteract `` bad '' immune cell damage beta cell . This study aim determine intranasal insulin protect beta cell stop progression diabetes individual risk .</brief_summary>
	<brief_title>Trial Intranasal Insulin Children Young Adults Risk Type 1 Diabetes</brief_title>
	<detailed_description>Autoimmune diseases outcome dysregulated immune response self-antigens . Type 1 diabetes ( T1D ) , previously know insulin-dependent juvenile diabetes , autoimmune disease body 's immune system react destroy insulin-producing β cell islets pancreas . T1D classically affect child young adult . Approximately 15 % people diabetes form disease treatment currently available prevent . Asymptomatic individual pre-clinical stage T1D identify presence circulate antibody islet autoantigens ( pro ) insulin , glutamic acid decarboxylase ( GAD ) tyrosine phosphatase-like insulinoma antigen 2 ( IA2 ) . ( Pro ) insulin autoantigen specific β cell several line evidence demonstrate play key role drive autoimmune β-cell destruction . The ability use self-antigens tool induce protective immunity , free side effect conventional non-specific immunosuppression , 'Holy Grail ' autoimmune disease therapy . Animal model provide proof-of-concept antigen-specific therapy . For example , non-obese diabetic ( NOD ) mouse , model spontaneous T1D , transgenic over-expression proinsulin antigen-presenting cell immune system development transfer bone marrow stem cell completely prevent diabetes . On practical translatable level , immune tolerance antigen achieve administer antigen mucosal immune system . Thus , immune response antigen suppress feeding antigen ( 'oral tolerance ' ) administer antigen naso-respiratory mucosa .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Benzalkonium Compounds</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<criteria>1 . Firstdegree seconddegree relative person Type 1 diabetes ( T1D ) diagnose age 40 . 2 . Age 430 year firstdegree relative ; age 420 year seconddegree relative . 3 . Confirmed serum antibody two islet antigen . 4 . Normal oral glucose tolerance test ( OGTT ) . 5 . First phase insulin response ( FPIR ) threshold Primary Stratum great equal 10th percentile sibling , offspring seconddegree relative person T1D ( great equal 100uU/ml age 8 year OR great equal 60 uU/ml age less 8 ) great equal 1st percentile parent someone T1D ( great ore equal 60uU/ml ) . Secondary Stratum : Greater equal 1st percentile , less 10th percentile sibling , offspring seconddegree relative someone T1D ( great equal 50uU/ml less 100 uU/ml age great equal 8 year great equal 20 uU/ml less 60uU/ml age less 8 year ) 6 . Provision write consent . 1 . History treatment insulin oral hypoglycemic agent 2 . Known diabetes ADA/WHO criteria 3 . Pregnant lactate childbearing potential use adequate method contraception 4 . Concomitant disease treatment may interfere assessment cause immunosuppression , judge investigator . 5 . Uncorrected vitamin D deficiency 6 . Known alcohol drug abuse , psychiatric condition could associate poor compliance . 7 . Known liver disease , persist elevation plasma Aspartate transaminase ( AST ) Alanine transaminase ( ALT ) level . 8 . Impaired renal function 9 . Any defect pathology nasal passage would preclude application intranasal spray .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Type 1 diabetes</keyword>
</DOC>